Travoprost Ophthalmic Solution, 0.004% Solution/ Drops
NDC Package 0378-9651-50
Package Information
Travoprost Ophthalmic Solution, 0.004% solution/ dropses is travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). This formulation utilizes a solution/ drops delivery system. Marketed by Mylan Pharmaceuticals Inc., this product is identified by NDC 0378-9651 and is authorized under FDA application ANDA205050.
Identification & Billing
- RxCUI: 284008 - travoprost 0.004 % Ophthalmic Solution
- RxCUI: 284008 - travoprost 0.04 MG/ML Ophthalmic Solution
- RxCUI: 284008 - travoprost 40 MCG/ML Ophthalmic Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0378 - Mylan Pharmaceuticals Inc.
- 0378-9651 - Travoprost Ophthalmic Solution, 0.004%
- 0378-9651-50 - 1 BOTTLE in 1 CARTON / 5 mL in 1 BOTTLE
- 0378-9651 - Travoprost Ophthalmic Solution, 0.004%
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0378-9651). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0378-9651-50 identifies a specific commercial package of 1 bottle in 1 carton / 5 ml in 1 bottle of Travoprost Ophthalmic Solution, 0.004%, a human prescription drug labeled by Mylan Pharmaceuticals Inc.. This solution/ drops is formulated for ophthalmic use and contains travoprost as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mylan Pharmaceuticals Inc. on December 18, 2019. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
How is this Mylan Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00378965150. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.